Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Total Liabilities: 2016-2024

Historic Total Liabilities for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $64.5 million.

  • Rocket Pharmaceuticals' Total Liabilities fell 14.95% to $54.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.4 million, marking a year-over-year decrease of 14.95%. This contributed to the annual value of $64.5 million for FY2024, which is 12.61% down from last year.
  • Rocket Pharmaceuticals' Total Liabilities amounted to $64.5 million in FY2024, which was down 12.61% from $73.8 million recorded in FY2023.
  • Rocket Pharmaceuticals' Total Liabilities' 5-year high stood at $87.3 million during FY2020, with a 5-year trough of $42.3 million in FY2021.
  • Its 3-year average for Total Liabilities is $66.8 million, with a median of $64.5 million in 2024.
  • In the last 5 years, Rocket Pharmaceuticals' Total Liabilities plummeted by 51.55% in 2021 and then skyrocketed by 46.87% in 2022.
  • Over the past 5 years, Rocket Pharmaceuticals' Total Liabilities (Yearly) stood at $87.3 million in 2020, then crashed by 51.55% to $42.3 million in 2021, then surged by 46.87% to $62.1 million in 2022, then climbed by 18.75% to $73.8 million in 2023, then decreased by 12.61% to $64.5 million in 2024.